Latest Market News

Noxopharm Limited has secured a major scientific milestone with the publication of its Sofra™ platform research in Nature Immunology, highlighting a novel anti-inflammatory mechanism with broad therapeutic potential.

Argenica Therapeutics has reported a significant increase in its half-year loss to $3.82 million, driven by reduced revenue and higher research and development expenses. The company continues to invest heavily in its neuroprotective drug candidate ARG-007 amid ongoing clinical trials.

Everest Metals Corporation is progressing rapidly with near-term gold production at its Mt Dimer Taipan and Revere Gold projects while simultaneously developing Australia’s first rubidium industry at Mt Edon. The company reports strong resource upgrades, ongoing mining, and promising pilot plant plans for critical minerals.

Cosmo Metals Limited has announced a fully underwritten entitlement offer to raise approximately $1.55 million, aimed at advancing drilling and exploration across its key gold and base metals projects. The offer includes new shares and attaching options, with funds earmarked for multiple projects in Western Australia and New South Wales.

Caprice Resources has confirmed significant extensions to high-grade gold mineralisation at its Vadrians system within the Island Gold Project, expanding the strike length to over 1,000 metres and depth to 400 metres. New discoveries and ongoing drilling signal strong growth potential in Western Australia's Murchison goldfields.

AGL Energy reported a 42% drop in statutory profit for the half-year ended December 2025, despite a modest revenue decline and growth in customer services. The company declared a higher interim dividend, underscoring confidence amid operational challenges and a strategic pivot to renewables.

James Hardie Industries reported a robust 30% jump in Q3 FY26 net sales, driven by the AZEK acquisition and growth in key regions, while operating income declined amid integration costs and market softness.

TruScreen has been confirmed as a superior primary cervical cancer screening device in the world’s largest opto-electronic study, outperforming traditional cytology and matching HPV testing accuracy.

SGH Limited has announced a fully franked ordinary dividend of AUD 0.32 per share for the six months ending December 2025, signalling steady returns for shareholders.

CSL Limited has released its half-year results showing a slight revenue decline amid ongoing transformation efforts, while maintaining its full-year guidance and expanding its share buyback program.

CSL Limited has announced an ordinary dividend of USD 1.30 per share for the six months ending December 2025, payable in April 2026 with multi-currency options for shareholders.

CSL Limited reported a 7% decline in underlying NPATA to US$1.9 billion for the half-year, weighed down by restructuring costs and impairments, yet maintains full-year guidance and expands its share buy-back program.